Blockchain Registration Transaction Record

Late-Stage Biopharmaceutical Company Clene (NASDAQ: CLNN) Enters Securities Purchase Agreement

Clene Inc., a late clinical-stage biopharmaceutical company, has entered into a securities purchase agreement, issuing 742,626 shares of common stock for an estimated $7.3 million. The company is focused on developing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

Late-Stage Biopharmaceutical Company Clene (NASDAQ: CLNN) Enters Securities Purchase Agreement

This news is important because it highlights a significant financial transaction for Clene Inc., a company dedicated to developing innovative therapies for neurodegenerative diseases. The agreement will provide the company with substantial gross proceeds, furthering its mission of improving mitochondrial health and protecting neuronal function.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xa3ef03def55c700e3cfd7a83978f1f7e1361056f72f89e9dd785c9ee31d15506
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintkeepwBne-5a82c40f0ad8cd45d742512c2de0e8d9